贝伐珠单抗联合卡培他滨维持对晚期结肠癌患者预后的影响
The Impact of Bevacizumab Combined with Capecitabine Maintenance on the Prognosis of Patients with Advanced Colorectal Cancer
胡丽霞 1汪超1
作者信息
- 1. 安徽医科大学附属巢湖医院肿瘤内科,安徽 巢湖 238000
- 折叠
摘要
目的:探究贝伐珠单抗联合卡培他滨维持对晚期结肠癌患者预后的影响.方法:收集2017 年1 月至2019 年1 月期间我院101 例晚期结肠癌患者的病例资料,所有患者均接受 5-氟尿嘧啶及卡培他滨为基础的贝伐珠单抗联合mFOLFOX6 或XELOX化疗一线化疗方案,其中42 例患者一线化疗后接受卡培他滨单药维持治疗,纳入对照组,59 例患者接受贝伐珠单抗联合卡培他滨维持治疗,纳入观察组,两组治疗均直至病情进展或毒副反应无法耐受.比较两组患者维持治疗时间和疾病控制时间,治疗前后Karnofsky功能状态评分(KPS)、美国东部肿瘤协作组体力状态评分(ZPS),血清肿瘤标志物水平,毒副反应以及远期预后情况.结果:观察组维持治疗时间、疾病控制时间均大于对照组(P<0.05);两组KPS均较治疗前升高,ZPS均较治疗前降低,观察组变化幅度均大于对照组(P<0.05);两组血清癌胚抗原(CEA)、唾液酸化盐藻戊糖(CA199)、胃癌抗原(CA724)水平均较治疗前降低,观察组变化幅度均大于对照组(P<0.05);两组毒副反应发生情况差异无统计学意义(P>0.05);观察组总生存率高于对照组(P<0.05).结论:晚期结肠癌一线治疗后贝伐珠单抗联合卡培他滨维持治疗安全有效,可延长生存时间,同时不良反应轻微.
Abstract
Objective:To explore the impact of bevacizumab combined with capecitabine maintenance on the prognosis of patients with advanced colorectal cancer.Methods:Clinical data of 101 patients with ad-vanced colorectal cancer treated in our hospital from January 2017 to January 2019 were collected.All patients received first-line chemotherapy based on 5-fluorouracil and capecitabine,combined with bevacizumab and mFOLFOX6 or XELOX regimen.Among them,42 patients received capecitabine monotherapy maintenance treatment after first-line chemotherapy(control group),and 59 patients received bevacizumab combined with capecitabine maintenance treatment(observation group).Both groups were treated until disease progression or intolerable toxic reactions.The maintenance treatment time,disease control time,Karnofsky Performance Sta-tus(KPS),Eastern Cooperative Oncology Group performance status(ZPS),serum tumor marker levels,ad-verse reactions,and long-term prognosis were compared between the two groups.Results:The maintenance treatment time and disease control time in the observation group were both longer than those in the control group(P<0.05).Both groups showed an increase in KPS and a decrease in ZPS after treatment,and the change in the observation group was greater than that in the control group(P<0.05).The serum levels of CEA,CA199,and CA724 in both groups decreased compared to before treatment,and the change in the ob-servation group was greater than that in the control group(P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).The overall survival rate in the observation group was higher than that in the control group(P<0.05).Conclusion:Bevacizumab com-bined with capecitabine maintenance treatment after first-line treatment for advanced colorectal cancer is safe and effective,prolonging survival time with mild adverse reactions.
关键词
晚期结肠癌/一线治疗/贝伐珠单抗/卡培他滨/肿瘤标志物Key words
Advanced colorectal cancer/First-line treatment/Bevacizumab/Capecitabine/Tumor markers引用本文复制引用
基金项目
安徽省自然科学基金(2018)(1808085QD110)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据